Health Care [ 6/12 ] | Biotechnology [ 43/73 ]
NASDAQ | Common Stock
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
It also engages in developing of CELsignia diagnostic platform.
The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib.
Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 25 | -1.04 Decreased by -67.74% | -0.88 Decreased by -18.18% |
| May 13, 25 | -0.85 Decreased by -33.58% | -0.86 Increased by +0.59% |
| Mar 25, 25 | -0.75 Decreased by -15.38% | -0.67 Decreased by -11.94% |
| Nov 11, 24 | -0.65 Increased by +21.69% | -0.70 Increased by +7.14% |
| Aug 14, 24 | -0.62 Increased by +6.06% | -0.68 Increased by +8.82% |
| May 15, 24 | -0.64 Decreased by -16.36% | -0.71 Increased by +9.86% |
| Mar 27, 24 | -0.65 Increased by +5.80% | -0.73 Increased by +10.96% |
| Nov 13, 23 | -0.83 Decreased by -13.70% | -0.68 Decreased by -22.06% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -45.27 M Decreased by -90.83% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -37.00 M Decreased by -71.18% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 121.34 K Decreased by -47.16% | -36.65 M Decreased by -94.46% | Decreased by -30.21 K% Decreased by -268.03% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -29.79 M Decreased by -61.87% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -23.72 M Decreased by -62.62% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -21.61 M Decreased by -81.03% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 229.65 K Increased by +N/A% | -18.85 M Decreased by -63.57% | Decreased by -8.21 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -18.40 M Decreased by -65.15% | Decreased by N/A% Decreased by N/A% |